Compare Aurinia Pharmaceuticals Inc. (AUPH) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock

Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 6.8x trailing P/E (16.9x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Aurinia Pharmaceuticals Inc. (AUPH) is the cheapest at 6.8x versus Regeneron Pharmaceuticals, Inc. at 18.8x. On forward P/E, Aurinia Pharmaceuticals Inc. is actually cheaper at 16.9x.

Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -2.1% for Aurinia Pharmaceuticals Inc. (AUPH). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AUPH returned +497.9% versus REGN's +104.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Aurinia Pharmaceuticals Inc.'s 0.64β — meaning AUPH is approximately 11% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 13% for Aurinia Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

Aurinia Pharmaceuticals Inc. (AUPH) is the more profitable company, earning 101.5% net margin versus 31.4% for Regeneron Pharmaceuticals, Inc. — meaning it keeps 101.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37.1% versus 25.7% for REGN. At the gross margin level — before operating expenses — AUPH leads at 88.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Aurinia Pharmaceuticals Inc. (AUPH) trades at 16.9x forward P/E versus 17.3x for Regeneron Pharmaceuticals, Inc. — 0.4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 9.7% to $857.17.

In this comparison, REGN (0.4% yield) pays a dividend. AUPH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc. (AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.64), +497.9% 10Y return). Both have compounded well over 10 years (AUPH: +497.9%, REGN: +104.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: AUPH is a small-cap deep-value stock; REGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.